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Abstract 
Developing new products and processes is increasingly a focal point of competition and often 
requires the development and successful implementation of novel process technologies.    The 
process development and production of a new discovery (new biological entity) are significantly 
more complex than for the production of small molecule drugs or new chemical entities.  
Conventional new product development models in the literature on firm level innovation do not 
capture the evidence we present on development projects for pharmaceuticals.   This paper shows 
why a new perspective is required to understand the management of product and process 
development for biopharmaceuticals and proposes an explanatory model for this purpose.  
 
1 Introduction 
Biotechnology is one of the fastest growing sectors in the global economy, especially as regards 
applications in the pharmaceutical sector, and has important implications for innovation theory 
and practice.  While the analytical distinction between product and process innovations has 
proved very useful in engineering-based industries, in life science based activity the distinction is 
less clear cut.  In this paper, we show the difficulties of trying to assign novel development in 
biopharmaceuticals either to the product innovation category or to the process innovation 
category, with reference to the transition between discovery and market launch.1  We find that 
product and process innovation categories are fuzzy sets in biopharmaceutical innovation; a 
fuzzy set is one whose members belong to it to some degree (Zadeh 1965).  It has become clear 
that in the biopharmaceutical sector, process development is an integral part of product 
development and that process innovation plays a key role in the transition of product from bench 
to market (Feldman & Ronzio, 2001; Pisano, 1997).  But implications of these findings have not 
been fully assimilated in innovation theory and bio-manufacturing investment practice.   
 
This article is organized in five parts.  The first part provides an overview of biopharmaceutical 
development and the second examines relevant theoretical perspectives.  In the third part, case 
study material is presented on the development process in new biopharmaceuticals.  The fourth 
part examines the case material in the light of theoretical approaches.  A new perspective for the 
understanding of biopharmaceutical development is proposed in the fifth part. 
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 This transition is referred to as ‘licensure’ for biologics and ‘approval’ for drugs (Vargo, 1998) 
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2 Overview of Biopharmaceutical Development 
Biotechnology, is ‘the application of scientific and engineering principles to the processing of 
materials by biological agents to provide goods and services” (OECD2).  As an enabling 
technology, biotechnology can trace its origin to fundamental disciplines including biology, 
genetics, engineering, chemistry and computer science (OECD).  Historically, biotechnology 
been involved in the production of wines, beers and cheese and has been viewed as an art as well 
as a science (Smith, 1996).  
 
The advances in genetic engineering3 and hybridoma technology made it commercially feasible 
to develop proteins with therapeutic applications in large quantities (Walsh, 1998).  Biomedical 
research undertaken in 1950s revealed that a host of molecules produced naturally in the body 
have therapeutic applications (Walsh, 1998).  They can now be produced in large quantities 
through the application of biotechnology principles.   It is often assumed that innovative activity 
is concentrated at the drug discovery stage of the development process and can be readily 
separated from the volume production of the newly discovered drug.  This assumption is 
congruent with findings from research on product and process innovation which are largely based 
on engineering industries rather than life science industries.   
 
3 Theoretical Perspectives 
Product development aims to improve the properties and performance of the finished product 
whereas process development is shaped by internal production objectives such as cost reduction 
and yields improvements (Lager, 2002; Pisano,1997).  Thus product innovation is seen to shift 
the demand for the product whereas process innovation reduces costs and shifts the supply curve 
(Pisano, 1997).  These issues can be approached from two perspectives.  Industrial economics 
examines differences in patterns of innovation across countries and industrial sectors, the 
evolution of particular technology over time, and intra-sector differences in the propensity of 
firms to innovate.  Research can also focus on the organisation, examining e.g. how specific 
products are developed (Brown & Eisenhardt, 1995). 
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 Recombinant DNA technologies genetic engineering procedures used to join together DNA segments from 
different origins in an environment outside a cell or organism.  This technique is perfected by Cohen and Boyer and 
used as a basis for much of the scientific progress that biotechnology has made in cloning cells and drug production  
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3.1 Industry Level – Life Cycle Model 
Understanding the dynamics of process and product development in industry development and 
competition has been shaped by the work of Abernathy and Utterback (1978). Their model 
addressed product innovation, process innovation and the competitive environment both at the 
level of the organizational and in relation to the life cycle of the industry itself.  They showed that 
during the emergence period, the rate of product innovation exceeds the rate of process 
innovation.  When a dominant design emerges, companies focus on process improvement to 
optimize the cost and quality of the product (Figure 1a). The model was further developed by 
Utterback (1994) to incorporate innovation in process industries (Figure 1b).  A brief review of 
this influential model will provide a basis for comparison with our findings.  
 
 
Figure 1:  Patterns of Innovation (Utterback, 1994) 
The emergence of a dominant design affects the characteristics of innovation of an industry and 
firms within it.   In assembled products, a dominant design is a synthesis based on earlier 
technological innovations which emerges after a period of experimentation in both the 
production and functionality of the product.  Once a dominant design emerges, other companies 
follow the new standard and seek economies of production (Utterback, 1994).  In industries that 
produce output other than assembled products, an enabling technology is seen to emerge after a 
period of variation and experimentation in the production process.  This allows the focus of 
technological effort to shift to process improvement rather than process innovation and design 
(ibid).  
 
Thus the life cycle model presents an analytical distinction between product and process 
innovation at the industry level.  In the case of assembled products, basic product concepts are 
formed in the early phase of the industry and once the dominant design emerges, opportunities 
for radical product innovation recede.  Firms in the industry tend to produce similar products and 
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the competitive basis rests on process innovation to lower the cost of production. Outside 
assembled product industries, process innovation takes a different form, often resulting in a 
converging and continuous production process, through the elimination of production steps4. 
Utterback (1994) used the plate glass industry to illustrate this point.  
 
3.2 Firm Level development Models 
To move from industry to firm level, there is a large and growing body of literature on the 
management of new product development.  The subject of process development for assembly-
based industry is often included as part of the overall product development of process.  However, 
researchers have been addressing the role of process development, especially in process 
industries (Pisano, 1997; Lager, 2002).  
       
3.2.1 Conventional New Product Development Models 
A comprehensive typology by Saren (1984) is relevant to our analysis.  He categorized new 
product development models into five types (1) departmental-stage models (2) activity-stage 
models (3) decision-stage models (4) conversion process models (5) response models.  
 
In departmental-stage models, product development process is based on ‘pass-the-parcel’ 
approach, with one functional group handing on to the next on completion of a task.  Functions 
are specialized and segmented (Takeuchi and Nonaka, 1986).  The departments or functions are 
held responsible for the various tasks carried out (Saren, 1984).  The development project moves 
sequentially from phase to phase.  One example of this model is the Phased Review Process 
developed by NASA in the 1960 (Cooper, 1994).  It is now widely accepted that this form of 
project management is deficient in several aspects.  First, overall control over the process is 
fragmented when sequences of tasks are isolated between departments.  Second, this method is 
time consuming. Third, there is no clear ownership of new product by any department.  Finally, 
there is no market feedback on the development process (Hard and Baker, 1994).   
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 “This phenomenon (process innovation) in nonassembled product lines appears to be linked not to product change 
but major equipment innovations, often those that combine in one step operations previously done in two or three 
separate steps.”  Page xxii  
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Activity-stage models are an improvement on the concept of departmental-based models in that 
development stages are characterized by certain activities which are supported by relevant 
departments.  Typically there is cross functional expertise involved in each stage.  But in practice 
the development process is prolonged by the passing of tasks from one department to the next.   
 
Decision-based models incorporate evaluation points between each stage of the process.  This 
approach identifies feedback loops overlooked in previous models.5    Many leading firms have 
accordingly developed a systematic stage-gate process: a road-map from idea to launch 
consisting of discrete stages, each stage preceded by a Go/ Kill decision point.   These firms 
include DuPont, 3M, HP and Procter & Gamble (Cooper, 1994).   
 
Conversion process models take a holistic view of new product development as a process by 
which input is converted into output, to avoid fragmented project management (Hart & Baker, 
1994).  Which conversion tasks  are undertaken depends on the nature of the innovation (Cooper, 
1982; Schon, 1967).  The conversion process is influenced by human, organization and resource-
related factors.  This approach comes closest to depicting the evidence we have observed. 
 
3.2.2  Firm level Process Development 
At firm level, the extensive literature on new product development models is not matched by 
similar studies in process based industries, which are rare. Lager (2000) introduces two such 
models.  The first involves four steps (1) Laboratory testing (2) Pilot plant testing (3) Trials in a 
demonstration plant (4) Production plant tests (See Figure 3).  He emphasizes the complex and 
sometimes chaotic nature of process development in process based industries.  
 
 
Figure 3:  A traditional model for process development (Lager, 2002) 
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 A related approach is the response model  which addresses reactions to such changes as new product ideas, or R&D 
project proposals in terms of acceptance or rejection (Hart and Baker, 1994). 
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The model depicted in Figure 3 applies to plant operations and does not deal with development 
projects. Another model, based on Utterback’s work, is provided by Lager to deal with the 
management of product or process development projects and comprises three development phase 
(See Figure 4).  This model does not show how process development might interact with product 
development.   
 
 
Figure 4:  A conceptual model for the ‘process development process’ (Lager, 2000) 
3.2.3 Firm level distinction between Product and Process Innovation 
The innovation literature we have been examining does not address the interaction of product and 
process development. For example, the models of new product development do not show how 
product and process innovation can be synchonised.  However, fast diffusing practices such as 
simultaneous engineering, cross-functional project teams, and design for manufacturability 
(Clark & Fujimoto, 1990, Ulrich & Eppinger, 2000) point to the importance of coordinating and 
integrating both process and product innovation. 
 
Pisano (1997) offered a different perspective on the relations between product and process 
innovation from that provided in the literature based on engineering industries.  He pointed out 
that the biopharmaceuticals industry is a process enabling industry, where both product and 
process technologies evolve rapidly and must be synchronized. The reasons for this emerge from 
the nature of biopharmaceutical production processes.  
 
3.3 Biopharmaceutical Development and Production 
3.3.1 Discovery 
Biopharmaceutical development starts with the identification of an agent with a desired 
biological profile.  At this stage a number of approaches are adopted.  These approaches range 
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from random screening of a wide range of biological materials to knowledge based drug 
identification.   Once a potential new drug is identified, it is then subjected to a range of tests, 
namely in-vitro and in animals in order to characterize it in terms of its safety and effectiveness 
in treating a disease (Walsh, 1998). 
 
3.3.2 Clinical Development 
Clinical development is done to gain approval for general medical use and to demonstrate the 
quality, safety and efficacy of any product (Walsh, 1998).  The overall clinical development of 
biopharmaceuticals up to market entry generally follows a standardized process consisting of six 
stages (Bergeron et. al., 2001).  These stages are discovery, pre-clinical, the three clinical phases 
(I, II, III) and finally the approval stage (ibid).   
 
Trial Phase Evaluation undertaken (and usual number of patients) Average duration 
(year) 
 
Phase 1  Safety testing in healthy human volunteers (20-80) 1 
 
Phase 2 Efficacy and safety testing in small number of patients (100-
300) 
 
2 
Phase 3 Large-scale efficacy and safety testing in substantial number 
of patients (1000-3000) 
 
3 
Phase 4 Post marketing safety surveillance undertaken for some 
drugs which are administered over particularly long period 
of time (number of patients vary) 
Several years 
Table 1: The clinical trial process (Walsh, 1998) 
 
Preclinical studies involve mainly pharmacological and toxicological assessment of the potential 
drug in animals.  Phase 1 trials involve measuring the tolerability and pharmacokinetics of the 
drug in healthy humans.  Phase 2 trials are carried out on a limited number of patients with the 
specific conditions.  The aim of this study is to identify the most appropriate dose, and to make 
an early assessment of whether the drug is effective for the proposed indication.  Phase 3 trials 
provide evidence of the safety and efficacy of a drug by studies in a large cohort of patients.  
Data from Phase 3 trials is important and typically forms the basis of the application to the 
regulators for approval to market the product.  The final phase is post marketing surveillance, 
which is sometimes referred to as Phase 4 trials.  This phase is conducted for some drugs 
especially those administered for a long period of time (Walsh, 1998). 
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3.3.3 Process Development and Production 
The bulk of biopharmaceuticals are produced through genetic engineering.  A recombinant 
“production system” is created, consisting of a genetically modified host cell (Smith, 1996).  
These “production systems” involve either microbial fermentation or processes involving 
mammalian cell culture.  The principles behind the large scale production processes of drug 
substances are derived from traditional fermentation technology which uses microorganisms for 
the production of required substances (Smith, 1996).  Fermentation involves a multitude of 
complex enzyme-catalysed reactions within specific microorganisms and hence is critically 
dependent on the process conditions and environment.  The process technologies of at this stage 
of production (upstream) are essentially based on growing large numbers of cells under 
controlled conditions.  These organisms must be cultivated in an optimum condition to form the 
desired products.   
 
Extraction and purification of desired proteins from the fermentation broth represents a large part 
of the overall production process of biopharmaceuticals (Smith, 1996).  During the extraction 
and purification stage (downstream), production processes are primarily concerned with initial 
separation of the bioreactor broth and subsequent concentration and purification of the desired 
product (Walsh, 1998).  The role of these processes is crucial in determining the final 
characteristics of the product such as purity and stability (Walsh, 1998). 
 
3.3.4 Biopharmaceutical Development Challenges and Goals 
Preclinical trials, clinical trials and product launch require the production of sufficient quantity 
and quality of product.  The material used for pre-clinical and clinical trials should be produced 
using the same process by which it is intended to undertake final-scale commercial manufacture 
(Walsh, 1998).  As such, extensive early development work is essential and the process 
developed be scalable and yields be improved.  Any significant deviation from the production 
protocol used to generate the trial material could invalidate the clinical trial results, because 
changes in the production process could potentially change the final product characteristics.  
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4 A Case Study – Development of a Novel Biopharmaceutical  
We now turn to evidence on product and process innovation from a biopharmaceutical case 
study.   
 
Product X is a virus vaccine which is able to protect the host without risk of infection through 
multiple-cycle replication because it lacks a gene.  The breakthrough in the discovery of Product 
X promised attractive clinical applications.  There was no pre-defined drug production process.  
As such, Company X had to develop a new, economically viable production process to make 
available supplies of the product for necessary development work as well as supplies of a 
marketable drug at a later stage6.   
 
In the course of the development project, three key processes (Process A, B and C) were 
developed.  Process A was developed during the initial stage of the development project and used 
to produce materials for the first part of Clinical Trial 1.  Process A is based on cell growth 
technology, on the surface of roller bottles and a simple harvesting method.  This method of 
production is not complex but yields Product X only at a low concentration.  Subsequently, data 
from Clinical Trial 1 called for a higher concentration.  Therefore, Company X had to modify 
Process A or develop a new process to meet the requirement.  Process B was developed to yield a 
higher concentration of Product X.  Process B was used for the supply of Product X for the later 
part of Clinical Trial 1 and for Clinical Trial 2. Although, Process B is also based on roller bottle 
cell growth technology, modifications were made to the downstream process.  The new Process 
B yields Product X at a higher concentration.  Process A and Process B were based on roller 
bottle method of production.  This method of production is simple, requires low upfront 
investment and is suitable for development work.  However, upon consideration of the potential 
market demand for Product X, it was decided that the roller bottle method of production was not 
the preferred option for a larger scale production in the long-term for the following reasons.  
First, roller bottle production is labour intensive.  Second, it produces low yields.  Third, it is not 
scalable (a liter of fermentation broth of microcarriers in liquid suspension is equivalent to 
approximately 100 roller bottles).  Process C was developed to meet the demands of a larger 
scale production.  The company intended to use Process C for the supply of materials for Clinical 
Trial 3 and subsequently for the market when the product is launched.   Process C is based on 
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 Product B failed during clinical trial 2.  However, the process development and manufacturing team developed the 
third process for the anticipation of Clinical Trial 3 and for subsequent in-market supplies.  
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cell growth on the surface of microcarriers in liquid suspension.  This method of production 
delivers higher yields per ml of fermentation broth and is more scalable.  The case summary is 
presented in Table 2. 
12 
 
 
Phase 1 Phase 2 Phase 3 
Development 
Goals 
 
Development for the supply of early 
stage clinical trials 
 
Development of a process that would 
yield higher concentration of product  
 
Development of a process for large scale 
production of materials for late stage clinical 
trial and for commercial application 
 
Clinical Trials 
 
 
Early part of clinical 1 
 
Later part of clinical 1 and clinical 2 
 
 
Clinical 3 
Process Design 
 
Cell growth on surface of roller bottles 
 
Scraping cells of the roller bottles and 
using centrifugal sucrose gradient for 
separation, harvesting cells using syringe 
Improved cell growth condition on 
surface of roller bottles 
 
Membrane filtration, and simple 
formulation methods 
Cell growth on surface of microcarriers 
 
Diafiltration and concentration method, freeze 
drying 
 
Product 
Specification 
and Yield 
 
 
Low virus titre7 limited by process 
 
 
Higher virus titre limited by process 
 
Virus titre not limited by process 
Resources 
 
In-house development 
 
Process development FTE8: ~12 
Project FTE: ~20 
Partnership with large pharma 
 
Process development FTE: ~15 
Project FTE: ~25 
Partnership with large pharme 
 
Process development FTE: ~30 
Project FTE: ~50 
Business Plan/ 
drivers 
 
Cost is not a major consideration 
 
Development time crucial 
Cost/ price of output becoming important 
 
Development time still important 
Cost/ price of output very important 
 
Distribution and marketing issues become 
relevant 
 
Table 2: Case summary
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 Virus titre is a measure of the concentration or activity of the vaccine 
8
 FTE: Full Time Equivalent of an employee 
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5 Discussion  
In this case, product and process development cannot be viewed as discrete activities. New 
chemical entities can be characterized by their chemical identity, but biological molecules are far 
more complex, context-specific and difficult to specify.  As a response to these difficulties, the 
process used to produce a particular batch of product is actually used for product definition and 
its specification is used for licensure application and regulatory purposes in the 
biopharmaceutical industry (Lubiniecki and Vargo, 1994).  
 
The distinction between product and process development is analytically useful and has helped to 
advance innovation theory when applied to engineering based industries.  But perspectives in the 
literature derived primarily from engineering-based industrie can be misleading when transferred 
to the biopharmaceutical industry, underpinned by the life sciences.  The key concept of 
‘enabling technology’  - as analogous to dominant design in product-based industries - is useful 
for explaining innovation in process-based engineering industries, but is not sufficient to explain 
production processes drawing on the life sciences.  There are important enabling biotechnologies, 
including the use of recombinant DNA and hybridomas, but these are generic technologies with a 
multitude of specialized applications. When attempts are first made to turn a molecular discovery 
into a drug, new processes must be developed and relatively little is known about their properties 
and dynamics.  This is illustrated by the case study evidence. 
 
We observe a multi-phased development path.  During the development of Product X, distinct 
objectives were set at the beginning of each phase. From one phase to another, development 
resources in terms of people, skills and equipment changed considerably.  There was a repeated 
need for innovations in process that were quite radical in terms of discontinuity from previous 
practice. These innovations were not only drivers of the economics and yields of the process but 
also altered the product characteristics.  Conventional new product development models like 
those summarized in Table 3,  which tend to characterise development stage as sequential steps 
from concept development through to ramp up, are misleading  when applied in this context.   
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New Product 
Development 
Stages 
Wheelwright 
and Clark 
(1992) 
Cooper 
(1994) 
Allen (1993) Schilling and 
Hill (1998) 
Gerwin 
(1993) 
Conceptual Concept 
Development 
Preliminary 
investigation 
Product 
concept 
definition 
 
Opportunity 
identification/ 
Concept 
Development 
Investigation 
of new 
technology 
Planning Product 
Planning 
Build business 
Case 
Program 
definition 
Product 
Design 
Initiate new 
product 
program 
Implementation Product/ 
Process 
Engineering 
 
Development Program 
implementatio
n 
Process 
Design 
Formal 
product 
concept & 
prototype 
Industrialisation Pilot 
Production/ 
Ramp-up 
Test and 
validate 
Industrialisati
on 
Commercial 
Production 
Testing, pre-
production 
and ramp-up 
Table 3:  Stages in New Product Development Processes (Source: Wheelwright and Clark 
(1992), Cooper (1994), Allen (1993), Schilling and Hill (1998), Gerwin (1993)) 
Key questions on the managerial aspects of biopharmaceutical development remain unaddressed.  
For example:  What are development steps and stages? How should performance be measured?  
These raise further questions about best practice in managing biopharmaceutical development 
projects.  A new approach is needed to understand the management of development projects in 
this life science based industry.  It is characterized by discontinuous innovations very different 
from those in engineering industries such as automobile and plate glass production.  
 
6 A New Perspective 
6.1 The Development Cycle 
Biopharmaceutical development usually involves novel techniques which were previously 
untried.  There is considerable uncertainty in the process technologies, shown in the discontinuity 
of process development efforts in the development project.  The iterative mode of the process 
development activity is conveyed by the concept of ‘development cycles’.   The development 
cycle involves agreeing and formulating objectives for the process design, taking into account the 
aims of the development, the resources available and the clinical milestone to be met at the 
particular phase.  A development cycle represents a distinct decision making phase in the overall 
product development project driven by some “primary objective”.         
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Figure 5: A Development Cycle 
 
6.2 The  Development Path 
Because most pharmaceutical development consists of new and untried techniques, the 
development process is iterative.  In contrast with development paths of other products described 
in the current literatures, the primary objective is continually revised as more is learned about 
very new technologies and  markets. Conceptually the overall development project of 
biopharmaceutical can be represented by Figure 6.   On completion of the development work, the 
product and process may look entirely different from those the team started with.  For example, 
the molecular structure is altered unpredictably by the scaling up process.   In the case of Product 
X, by the end of the development project, the production process had been transformed as 
compared with that used initially. The product was also different in terms of the concentration 
and activity of the vaccine (virus titre).  
 
 
 
Figure 6:  A multi-phase development path 
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6.3 Summary and Further Work  
We have explored the difficulties of trying to assign novel development in biopharmaceuticals 
either to the product innovation category or to the process innovation category, with reference to 
the transition between discovery and market launch.9  In the innovation literature, product and 
process innovation are addressed at an industry level where they are viewed as different in 
characteristic and roles.  We argue that this view can be misleading when applied to the 
biopharmaceutical industry.  At the firm level, we observed that the development path of 
biopharmaceutical is multi-phased and interlinked in ways that conventional new product 
development models do not allow for.  A different approach is needed for the management of 
biopharmaceutical development and strategy. 
 
We offer a development model showing how product and process innovation develop in 
conjunction with each other.  This raises issues of development; how do these activities interact 
with each other and evolve along a development path? The implication of these activities for the 
design of business models requires further investigation.  The difference in development paths 
for novel products will be contrasted with products with expiring patents (bio-generics).  The 
context in which bio-generics are developed is different from that of novel biologics.  For 
example, the regulatory milestones and requirements to obtain licensure are not identical to those 
of from novel biologics.  In addition, business models and competitive strategies of bio-generics 
firms tend to be different from businesses competing on the basis of novel discovery, 
development and production of new biological entities.  We conclude by raising some salient 
issues for business models of biopharmaceuticals companies. 
 
7 Implication for Business Models 
In place of a dichotomy between product and process innovation in the biopharmaceutical 
industry, we would emphasise a distinction between two other aspects of innovation, namely 
technological innovation and innovation in business models.  Business models are an important 
dimension of innovation, offering new ways to organize the creation, delivery and capture of 
value.  For example, licensing models and marketing models in the semi-conductors and PC 
sectors have proved important sources of innovation.  There are many types of business model in 
the biopharmaceutical industry, reflecting differing strategic perspectives and realities. The main 
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 This transition is referred to as ‘licensure’ for biologics and ‘approval’ for drugs (Vargo, 1998) 
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variants include (1) Specialised discovery based business models (2) Discovery and development 
models (3) Hybrid models (4) Fully integrated drug production models (Garnsey 2003 p.114) The 
idea that new ventures should use the principle of comparative advantage to specialize in drug 
discover (product innovation) while established companies specialize in producing and scaling 
up the drug (introducing suitable process innovations), has been widely accepted as best practice.  
The distinction is congruent with influential theoretical perspectives that posit a sharp distinction 
between product and process innovation and view product development as made up of distinct 
and sequential stages.  However there are implications for strategy in our findings in that 
biopharmaceutical activity, product and process development activities are interlinked.  During 
the development of at least some biologics, product and process innovation advance in iteration.  
In the case investigated, the process constitutes the product.  Industry regulations indicate that the 
nature of the drug required for efficacy can only be known through detailed process development.  
Our observations support evidence presented by Feldman and Ronzio (2001) who found that US 
biotech entrepreneurs preferred to own and control their manufacturing facilities if funding 
permitted, because they saw disadvantages in separating advances in product innovation from 
advances in processes. Production experience in biopharmaceuticals provides a source of 
knowledge that supports effective product-process innovation.  How sound are business models 
based on a false dichotomy between product and process innovation? Dividing bio-processing 
activities from R&D in separate businesses may inhibit the development of the kind of 
scientifically grounded but practical expertise required for knowledge-intensive bio-processing.  
This issue points to a further agenda for research. 
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